3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Ovarian Carcinosarcoma
1
Interventions
Paclitaxel
41
Specimen Handling
36
Carboplatin
34
pembrolizumab
32
Bevacizumab
32
Magnetic Resonance Spectroscopy
29
olaparib
19
liposomal doxorubicin
16
Cisplatin
16
Biopsy
16
Gemcitabine
15
Taxes
12
Nivolumab
12
Immunoglobulin G
11
Disulfides
11
Cyclophosphamide
11
Topotecan
10
Doxorubicin
10
fludarabine
9
niraparib
7
mirvetuximab soravtansine
7
Fulvestrant
7
trastuzumab deruxtecan
6
palbociclib
6
durvalumab
6
Surveys and Questionnaires
6
Megestrol Acetate
6
lenvatinib
5
dostarlimab
5
Radiation
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Antineoplastic Agents
×
Gynecologic
×
30 days
×
Clear all
NCT03651206
2026-06-01
ROCSAN
ARCAGY/ GINECO GROUP
Phase 2/3
Recruiting
138 enrolled